TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors
Brief Summary: The purpose of this research study is to learn about the effects of supplemental intranasal oxytocin as a treatment for improving social difficulties in children and adolescents with autism. This study will also provide additional information about the safety and tolerability of intranasal oxytocin. Investigators expect oxytocin will increase social motivation, improving daily living skills and quality of life.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: RG7314; Type: EXPERIMENTAL; Interventions: Drug: RG7314 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: RG7314; Assigned to Arm(s): RG7314
B: Arm Label: DB Placebo Nasal Spray; Type: PLACEBO_COMPARATOR; Interventions: Drug: Double blind phase Placebo Nasal Spray | Arm Label: DB Oxytocin Nasal Spray; Type: ACTIVE_COMPARATOR; Interventions: Drug: double Blind Oxytocin Nasal Spray | Arm Label: open label intranasal oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Open Label intranasal oxytocin | Intervention Type: DRUG; Name: Double blind phase Placebo Nasal Spray; Assigned to Arm(s): DB Placebo Nasal Spray | Intervention Type: DRUG; Name: double Blind Oxytocin Nasal Spray; Assigned to Arm(s): DB Oxytocin Nasal Spray | Intervention Type: DRUG; Name: Open Label intranasal oxytocin; Assigned to Arm(s): open label intranasal oxytocin
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Balovaptan (RO5285119) 10 mg/d equivalent; Type: EXPERIMENTAL; Interventions: Drug: RO5285119 | Arm Label: Balovaptan (RO5285119) 4 mg/d equivalent; Type: EXPERIMENTAL; Interventions: Drug: RO5285119 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: RO5285119; Assigned to Arm(s): Balovaptan (RO5285119) 10 mg/d equivalent, Balovaptan (RO5285119) 4 mg/d equivalent
D: Arm Label: A1; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: A2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): A1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors
Brief Summary: The purpose of this research study is to learn about the effects of supplemental intranasal oxytocin as a treatment for improving social difficulties in children and adolescents with autism. This study will also provide additional information about the safety and tolerability of intranasal oxytocin. Investigators expect oxytocin will increase social motivation, improving daily living skills and quality of life.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Vasopressin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vasopressin | Intervention Type: DRUG; Name: Vasopressin; Assigned to Arm(s): Vasopressin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Atomoxetine; Type: EXPERIMENTAL; Interventions: Drug: Atomoxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Atomoxetine; Assigned to Arm(s): Atomoxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: DB Placebo Nasal Spray; Type: PLACEBO_COMPARATOR; Interventions: Drug: Double blind phase Placebo Nasal Spray | Arm Label: DB Oxytocin Nasal Spray; Type: ACTIVE_COMPARATOR; Interventions: Drug: double Blind Oxytocin Nasal Spray | Arm Label: open label intranasal oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Open Label intranasal oxytocin | Intervention Type: DRUG; Name: Double blind phase Placebo Nasal Spray; Assigned to Arm(s): DB Placebo Nasal Spray | Intervention Type: DRUG; Name: double Blind Oxytocin Nasal Spray; Assigned to Arm(s): DB Oxytocin Nasal Spray | Intervention Type: DRUG; Name: Open Label intranasal oxytocin; Assigned to Arm(s): open label intranasal oxytocin
D: Arm Label: Intranasal Oxytocin (Syntocinon); Type: EXPERIMENTAL; Interventions: Drug: Intranasal Oxytocin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Intranasal Oxytocin; Assigned to Arm(s): Intranasal Oxytocin (Syntocinon) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors
Brief Summary: The purpose of this research study is to learn about the effects of supplemental intranasal oxytocin as a treatment for improving social difficulties in children and adolescents with autism. This study will also provide additional information about the safety and tolerability of intranasal oxytocin. Investigators expect oxytocin will increase social motivation, improving daily living skills and quality of life.


Options:
A: Arm Label: DB Placebo Nasal Spray; Type: PLACEBO_COMPARATOR; Interventions: Drug: Double blind phase Placebo Nasal Spray | Arm Label: DB Oxytocin Nasal Spray; Type: ACTIVE_COMPARATOR; Interventions: Drug: double Blind Oxytocin Nasal Spray | Arm Label: open label intranasal oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Open Label intranasal oxytocin | Intervention Type: DRUG; Name: Double blind phase Placebo Nasal Spray; Assigned to Arm(s): DB Placebo Nasal Spray | Intervention Type: DRUG; Name: double Blind Oxytocin Nasal Spray; Assigned to Arm(s): DB Oxytocin Nasal Spray | Intervention Type: DRUG; Name: Open Label intranasal oxytocin; Assigned to Arm(s): open label intranasal oxytocin
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: RG7314; Type: EXPERIMENTAL; Interventions: Drug: RG7314 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: RG7314; Assigned to Arm(s): RG7314
C: Arm Label: Aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripiprazole | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: citalopram hydrobromide; Type: EXPERIMENTAL; Interventions: Drug: citalopram hydrobromide | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: citalopram hydrobromide; Assigned to Arm(s): citalopram hydrobromide | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Interest of the Association of Two Complementary Techniques, Hypnosis and Transcutaneous Electrical Nerve Stimulation in the Treatment of Chronic Non-cancer Pain, Nociceptive and / or Neuropathic Pain: Randomized Trial
Brief Summary: At Saint-Antoine's hospital, in CETD a multidisciplinary team takes care of patients with chronic pain. Free-drug techniques are available to reduce their consumption of analgesics. This study is to assess the relief obtained by the simultaneous combination of these two techniques: transcutaneous electrical nerve stimulation and hypnosis.


Options:
A: Arm Label: TENS; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Transcutaneous electrical nerve stimulation | Arm Label: TENS and hypnosis.; Type: EXPERIMENTAL; Interventions: Behavioral: Transcutaneous electrical nerve stimulation and hypnosis | Intervention Type: BEHAVIORAL; Name: Transcutaneous electrical nerve stimulation; Assigned to Arm(s): TENS | Intervention Type: BEHAVIORAL; Name: Transcutaneous electrical nerve stimulation and hypnosis; Assigned to Arm(s): TENS and hypnosis.
B: Arm Label: Sequence 1; Type: OTHER; Interventions: Device: High frequency spinal cord stimulation | Arm Label: Sequence 2; Type: OTHER; Interventions: Device: High frequency spinal cord stimulation | Intervention Type: DEVICE; Name: High frequency spinal cord stimulation; Assigned to Arm(s): Sequence 1, Sequence 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: PEPT | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: CBO standard | Intervention Type: PROCEDURE; Name: PEPT; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: CBO standard; Assigned to Arm(s): 2
D: Arm Label: Burst SCS; Type: EXPERIMENTAL; Interventions: Procedure: Burst Spinal Cord Stimulation, Procedure: Sham spinal cord stimulation, Device: SCS implant | Arm Label: Sham SCS; Type: SHAM_COMPARATOR; Interventions: Procedure: Burst Spinal Cord Stimulation, Procedure: Sham spinal cord stimulation, Device: SCS implant | Intervention Type: PROCEDURE; Name: Burst Spinal Cord Stimulation; Assigned to Arm(s): Burst SCS, Sham SCS | Intervention Type: PROCEDURE; Name: Sham spinal cord stimulation; Assigned to Arm(s): Burst SCS, Sham SCS | Intervention Type: DEVICE; Name: SCS implant; Assigned to Arm(s): Burst SCS, Sham SCS

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Simvastatin on Th17 Cytokines and Th17 Polarizing Cytokines in COPD Patients
Brief Summary: Airway inflammation is partly driven by Th17 and Th17-polarizing cytokines that is steroid-resistant. Statins could suppress IL-17 cytokines in other diseases such as atherosclerosis and multiple sclerosis in mouse model. The investigators hypothesize that statins might provide anti-inflammatory benefit of suppressing IL-17 cytokines in COPD patients.


Options:
A: Arm Label: Simvastatin; Type: EXPERIMENTAL; Interventions: Drug: simvastatin, placebo | Arm Label: B1-6-12; Type: PLACEBO_COMPARATOR; Interventions: Drug: simvastatin, placebo | Intervention Type: DRUG; Name: simvastatin, placebo; Assigned to Arm(s): B1-6-12, Simvastatin
B: Arm Label: Lactose tablet; Type: PLACEBO_COMPARATOR; Interventions: Drug: Lactose tablet | Arm Label: Simvastatin 20mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Simvastatin | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): Simvastatin 20mg | Intervention Type: DRUG; Name: Lactose tablet; Assigned to Arm(s): Lactose tablet
C: Arm Label: COPD subjects; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Non-smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Intervention Type: OTHER; Name: Novel endpoint determination; Assigned to Arm(s): COPD subjects, Non-smoker controls, Smoker controls
D: Arm Label: Atorvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin, Drug: Formoterol | Arm Label: Lactose tablet; Type: PLACEBO_COMPARATOR; Interventions: Drug: Formoterol, Drug: Lactose tablet | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Atorvastatin | Intervention Type: DRUG; Name: Formoterol; Assigned to Arm(s): Atorvastatin, Lactose tablet | Intervention Type: DRUG; Name: Lactose tablet; Assigned to Arm(s): Lactose tablet

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Iota-Carrageenan Nasal Spray 1.2 g/l (0.12 Percent) (Bisolviral) Versus Placebo Nasal Spray in the Early Treatment of Common Cold
Brief Summary: The aim of this clinical trial is to investigate the effect of Iota-Carrageenan treatment on cold symptoms. The effect of treatment on the duration of the cold and the patients viral load plus cytokine level indicating the inflammatory response will be analyzed.


Options:
A: Arm Label: Povidone-Iodine 0.2% (BETADINE®); Type: EXPERIMENTAL; Interventions: Drug: Gargle/Mouthwash | Arm Label: Hydrogen peroxide 1% (ActiveOxy); Type: EXPERIMENTAL; Interventions: Drug: Gargle/Mouthwash | Arm Label: Neem extract (Azadirachta indicia); Type: ACTIVE_COMPARATOR; Interventions: Drug: Gargle/Mouthwash | Arm Label: Hypertonic saline (2%NaCl); Type: ACTIVE_COMPARATOR; Interventions: Drug: Gargle/Mouthwash | Arm Label: Positive controls; Type: PLACEBO_COMPARATOR; Interventions: Drug: Gargle/Mouthwash | Intervention Type: DRUG; Name: Gargle/Mouthwash; Assigned to Arm(s): Hydrogen peroxide 1% (ActiveOxy), Hypertonic saline (2%NaCl), Neem extract (Azadirachta indicia), Positive controls, Povidone-Iodine 0.2% (BETADINE®)
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Device: Placebo | Arm Label: Iota-Carrageenan nasal spray; Type: EXPERIMENTAL; Interventions: Device: Iota-Carrageenan | Intervention Type: DEVICE; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DEVICE; Name: Iota-Carrageenan; Assigned to Arm(s): Iota-Carrageenan nasal spray
C: Arm Label: mouth rinse with antiviral; Type: ACTIVE_COMPARATOR; Interventions: Device: mouthrinse with bêta-cyclodextrin and citrox | Arm Label: mouth rinse without antiviral; Type: PLACEBO_COMPARATOR; Interventions: Device: mouthrinse without bêta-cyclodextrin and citrox | Intervention Type: DEVICE; Name: mouthrinse with bêta-cyclodextrin and citrox; Assigned to Arm(s): mouth rinse with antiviral | Intervention Type: DEVICE; Name: mouthrinse without bêta-cyclodextrin and citrox; Assigned to Arm(s): mouth rinse without antiviral
D: Arm Label: Vitamin D and gargling; Type: EXPERIMENTAL; Interventions: Dietary Supplement: cholecalciferol (vitamin D3), Behavioral: Gargling | Arm Label: Vitamin D and general health advice; Type: EXPERIMENTAL; Interventions: Dietary Supplement: cholecalciferol (vitamin D3) | Arm Label: Placebo and general health advice; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Placebo and gargling; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Gargling, Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: cholecalciferol (vitamin D3); Assigned to Arm(s): Vitamin D and gargling, Vitamin D and general health advice | Intervention Type: BEHAVIORAL; Name: Gargling; Assigned to Arm(s): Placebo and gargling, Vitamin D and gargling | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo and gargling, Placebo and general health advice

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Iota-Carrageenan Nasal Spray 1.2 g/l (0.12 Percent) (Bisolviral) Versus Placebo Nasal Spray in the Early Treatment of Common Cold
Brief Summary: The aim of this clinical trial is to investigate the effect of Iota-Carrageenan treatment on cold symptoms. The effect of treatment on the duration of the cold and the patients viral load plus cytokine level indicating the inflammatory response will be analyzed.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Device: Placebo | Arm Label: Iota-Carrageenan nasal spray; Type: EXPERIMENTAL; Interventions: Device: Iota-Carrageenan | Intervention Type: DEVICE; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DEVICE; Name: Iota-Carrageenan; Assigned to Arm(s): Iota-Carrageenan nasal spray
B: Arm Label: Vitamin D and gargling; Type: EXPERIMENTAL; Interventions: Dietary Supplement: cholecalciferol (vitamin D3), Behavioral: Gargling | Arm Label: Vitamin D and general health advice; Type: EXPERIMENTAL; Interventions: Dietary Supplement: cholecalciferol (vitamin D3) | Arm Label: Placebo and general health advice; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Placebo and gargling; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Gargling, Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: cholecalciferol (vitamin D3); Assigned to Arm(s): Vitamin D and gargling, Vitamin D and general health advice | Intervention Type: BEHAVIORAL; Name: Gargling; Assigned to Arm(s): Placebo and gargling, Vitamin D and gargling | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo and gargling, Placebo and general health advice
C: Arm Label: mouth rinse with antiviral; Type: ACTIVE_COMPARATOR; Interventions: Device: mouthrinse with bêta-cyclodextrin and citrox | Arm Label: mouth rinse without antiviral; Type: PLACEBO_COMPARATOR; Interventions: Device: mouthrinse without bêta-cyclodextrin and citrox | Intervention Type: DEVICE; Name: mouthrinse with bêta-cyclodextrin and citrox; Assigned to Arm(s): mouth rinse with antiviral | Intervention Type: DEVICE; Name: mouthrinse without bêta-cyclodextrin and citrox; Assigned to Arm(s): mouth rinse without antiviral
D: Arm Label: Povidone-Iodine 0.2% (BETADINE®); Type: EXPERIMENTAL; Interventions: Drug: Gargle/Mouthwash | Arm Label: Hydrogen peroxide 1% (ActiveOxy); Type: EXPERIMENTAL; Interventions: Drug: Gargle/Mouthwash | Arm Label: Neem extract (Azadirachta indicia); Type: ACTIVE_COMPARATOR; Interventions: Drug: Gargle/Mouthwash | Arm Label: Hypertonic saline (2%NaCl); Type: ACTIVE_COMPARATOR; Interventions: Drug: Gargle/Mouthwash | Arm Label: Positive controls; Type: PLACEBO_COMPARATOR; Interventions: Drug: Gargle/Mouthwash | Intervention Type: DRUG; Name: Gargle/Mouthwash; Assigned to Arm(s): Hydrogen peroxide 1% (ActiveOxy), Hypertonic saline (2%NaCl), Neem extract (Azadirachta indicia), Positive controls, Povidone-Iodine 0.2% (BETADINE®)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Advance Care Planning: A Way to Improve End-of-life Care
Brief Summary: Communication about end-of-life issues is often suboptimal. A way to improve the quality of end-of-life care is Advance Care Planning (ACP). ACP is a discussion between an incurable ill patient and the health professionals about preferences for end-of-life care. In Denmark, there is no tradition of systematic communication with patients about end-of-life care. The aim is to investigate how ACP can be beneficial among incurable ill patients treated in an outpatient context and if the concept is feasible in a Danish context. The study is designed as a prospective randomised controlled trial. Patients from relevant departments will be included and randomised in two groups: one receiving usual care and the other receiving usual care and ACP. Data will be collected from Electronic Patient Files and from questionnaires. If ACP is effective, it will improve the quality of end-of-life care for patients and their families and reduce the psychological distress in the bereaved relatives.


Options:
A: Arm Label: Control: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: DT LVAD Decision Support Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: DT LVAD Decision Support Intervention | Intervention Type: BEHAVIORAL; Name: DT LVAD Decision Support Intervention; Assigned to Arm(s): DT LVAD Decision Support Intervention
B: Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Video Arm; Type: EXPERIMENTAL; Interventions: Behavioral: Video decision aid | Intervention Type: BEHAVIORAL; Name: Video decision aid; Assigned to Arm(s): Video Arm
C: Arm Label: Intervention: ACP conversation; Type: EXPERIMENTAL; Interventions: Behavioral: ACp conversation | Arm Label: No intervention: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ACp conversation; Assigned to Arm(s): Intervention: ACP conversation
D: Arm Label: ADAPT Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: ADAPT Intervention | Arm Label: Enhanced usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ADAPT Intervention; Assigned to Arm(s): ADAPT Intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Study of Intensified Chemotherapy and Simultaneous Treatment With Heparin in Out-patients With Pancreatic Cancer.
Brief Summary: Venous thromboembolic events are considered to be a prognostic negative factor and small studies showed astonishing survival advantages using heparin as prophylactic treatment to prevent venous thromboembolic events. Based on these assumptions our Charité - Onkologie (CONKO) study group planned to conduct a randomized trial to investigate the impact of low molecular weight heparin (LMWH) in a prospective setting in patients with advanced pancreatic cancer undergoing first line therapy, the CONKO-004 trial. During the preliminary stages we had to undertake a pilot trial to get information on safety and feasibility of combined chemotherapy with simultaneous treatment of the LMWH Enoxaparin in patients with advanced pancreatic cancer who are at high risk of gastrointestinal bleeding due to local cancer spread.


Options:
A: Arm Label: short heparin; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: extended heparin; Type: EXPERIMENTAL; Interventions: Drug: Heparin, Low-Molecular-Weight | Intervention Type: DRUG; Name: Heparin, Low-Molecular-Weight; Assigned to Arm(s): extended heparin
B: Arm Label: GFFC + LMWH; Type: EXPERIMENTAL; Interventions: Drug: Enoxaparine | Intervention Type: DRUG; Name: Enoxaparine; Assigned to Arm(s): GFFC + LMWH
C: Arm Label: Edoxaban group; Type: EXPERIMENTAL; Interventions: Drug: Edoxaban, Drug: Low molecular weight heparin | Arm Label: Dalteparin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dalteparin | Intervention Type: DRUG; Name: Edoxaban; Assigned to Arm(s): Edoxaban group | Intervention Type: DRUG; Name: Dalteparin; Assigned to Arm(s): Dalteparin group | Intervention Type: DRUG; Name: Low molecular weight heparin; Assigned to Arm(s): Edoxaban group
D: Arm Label: High Risk for VTE recieving dalteparin; Type: EXPERIMENTAL; Interventions: Drug: dalteparin injection | Arm Label: High Risk for VTE No therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Low Risk for VTE; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: dalteparin injection; Assigned to Arm(s): High Risk for VTE recieving dalteparin

Answer: B